LockThis Alphavalue article, the European leader in independent research, is only available to subscribers .
Alphavalue is exclusively on MarketScreener.
To unlock the article, SUBSCRIBE!
Already a customer? Log In
Sanofi: revised financial statements excluding Opella 03:48am CF
Novavax to sell Czech manufacturing unit to Novo Nordisk for $200 million Dec. 04 RE
Sanofi to Invest 1 Billion Euros for New Insulin Facility in Beijing Dec. 04 MT
Health Care Down, But Near All-Time Highs, as Biotech Firms Gain -- Health Care Roundup Dec. 03 DJ
Global markets live: Apple, Tesla, Blackrock, Intel, Microsoft... Dec. 03Our Logo
CAC40: up despite political crisis in France Dec. 03 CF
SANOFI : Deutsche Bank maintains a Sell rating Dec. 03 ZD
Sanofi: billion euro investment in China Dec. 03 CF
OSE Immunotherapeutics Names Chief Corporate Affairs, Investor Relations Officer Dec. 03 MT
SANOFI : JP Morgan sticks Neutral Dec. 03 ZD
Sanofi to Invest $1.05 Billion in New Insulin Manufacturing Base in China Dec. 03 DJ
Sanofi Plans EUR1 Billion Chinese Insulin Production Facility Dec. 02 MT
Sanofi announces an investment of nearly one billion euros in China Dec. 02 RE
Sanofi announces its biggest China investment deal amid China-EU trade tensions Dec. 02 RE
Astrazeneca's Enhertu, Orpathys Among 91 Drugs Added to China's National Reimbursement Drug List Nov. 29 MT
Intron Health Downgrades Sanofi to Hold, Lowers PT Nov. 29 MT
Sanofi Opens Second Manufacturing Plant in Singapore Nov. 27 MT
Sanofi Opens New $600 Million Vaccines Facility in Singapore Nov. 27 MT
Global markets live: Tesla, Rivian, Zoom, Roche, Unicredit... Nov. 26Our Logo
NSC Sanofi and A*STAR Enter Agreement to Further Research on Acne Treatment Nov. 26 MT
Sanofi Plans Revisions on Discount Policy for Certain US Hospitals Nov. 24 MT
Health Care Stocks Are Little Changed -- Health Care Roundup Nov. 22 DJ
Sanofi plans to change hospital drug-discount program, WSJ reports Nov. 22 RE
Sanofi Plans Drug Discount Policy Restriction Nov. 22 MT
CIC Market Solutions Upgrades Sanofi to Buy Nov. 22 MT
Chart Sanofi
SAN: Dynamic Chart
Logo Sanofi
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).
Employees
86,088
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
surperformance-ratings-light-chart SANOFIMore Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
91.80EUR
Average target price
114.09EUR
Spread / Average Target
+24.28%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. SAN Stock
  4. News Sanofi
  5. Sanofi: Sanofi’s healthy Q1 performance hailed by markets